Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
Status:
Terminated
Trial end date:
2017-03-06
Target enrollment:
Participant gender:
Summary
This trial will assess the 6-month complete response rate and toxicity profile of oral
dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3
mutations or over-expression who are ineligible for or refusing cystectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Noah Hahn, M.D.
Collaborators:
Hoosier Cancer Research Network Novartis Pharmaceuticals